These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 11076665)

  • 1. Exploiting changes in the tumour microenvironment with sequential cytokine and matrix metalloprotease inhibitor treatment in a murine breast cancer model.
    Scott KA; Holdsworth H; Balkwill FR; Dias S
    Br J Cancer; 2000 Dec; 83(11):1538-43. PubMed ID: 11076665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potentiated antitumor effects of interleukin 12 and matrix metalloproteinase inhibitor batimastat against B16F10 melanoma in mice.
    Dabrowska A; Giermasz A; Marczak M; Gołab J; Jakóbisiak M
    Anticancer Res; 2000; 20(1A):391-4. PubMed ID: 10769685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts.
    Giavazzi R; Garofalo A; Ferri C; Lucchini V; Bone EA; Chiari S; Brown PD; Nicoletti MI; Taraboletti G
    Clin Cancer Res; 1998 Apr; 4(4):985-92. PubMed ID: 9563894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The matrix metalloproteinase inhibitor batimastat (BB-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice.
    Low JA; Johnson MD; Bone EA; Dickson RB
    Clin Cancer Res; 1996 Jul; 2(7):1207-14. PubMed ID: 9816289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis.
    Krüger A; Soeltl R; Sopov I; Kopitz C; Arlt M; Magdolen V; Harbeck N; Gänsbacher B; Schmitt M
    Cancer Res; 2001 Feb; 61(4):1272-5. PubMed ID: 11245418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94.
    Asahi M; Asahi K; Jung JC; del Zoppo GJ; Fini ME; Lo EH
    J Cereb Blood Flow Metab; 2000 Dec; 20(12):1681-9. PubMed ID: 11129784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of bleomycin-induced pulmonary fibrosis in mice by the matrix metalloproteinase inhibitor batimastat.
    Corbel M; Caulet-Maugendre S; Germain N; Molet S; Lagente V; Boichot E
    J Pathol; 2001 Apr; 193(4):538-45. PubMed ID: 11276015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein.
    Huang X; Wong MK; Yi H; Watkins S; Laird AD; Wolf SF; Gorelik E
    Cancer Res; 2002 Oct; 62(20):5727-35. PubMed ID: 12384531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-invasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2,4,6-trione derivative, an orally active and selective matrix metalloproteinases inhibitor.
    Maquoi E; Sounni NE; Devy L; Olivier F; Frankenne F; Krell HW; Grams F; Foidart JM; Noël A
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4038-47. PubMed ID: 15217936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An MMP-2/MMP-9 inhibitor, 5a, enhances apoptosis induced by ligands of the TNF receptor superfamily in cancer cells.
    Nyormoi O; Mills L; Bar-Eli M
    Cell Death Differ; 2003 May; 10(5):558-69. PubMed ID: 12728254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene transfer of matrix metalloproteinase-9 induces tumor regression of breast cancer in vivo.
    Bendrik C; Robertson J; Gauldie J; Dabrosin C
    Cancer Res; 2008 May; 68(9):3405-12. PubMed ID: 18451168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngeneic model of breast cancer.
    Guo Y; Mazar AP; Lebrun JJ; Rabbani SA
    Cancer Res; 2002 Aug; 62(16):4678-84. PubMed ID: 12183425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Protective role of MMP-9 inhibitor batimastat in acute lung injury after cardiopulmonary bypass].
    Ge SL; Gong WH; Zhang CX; Zhang L; Han PH; Zhang SQ; Feng JB; Zhou DC
    Zhonghua Wai Ke Za Zhi; 2010 Jan; 48(1):57-61. PubMed ID: 20302758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thermolysin activates equine lamellar hoof matrix metalloproteinases.
    Mungall BA; Pollitt CC
    J Comp Pathol; 2002 Jan; 126(1):9-16. PubMed ID: 11814317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel matrix metalloproteinase inhibitor, FYK-1388 suppresses tumor growth, metastasis and angiogenesis by human fibrosarcoma cell line.
    Shinoda K; Shibuya M; Hibino S; Ono Y; Matsuda K; Takemura A; Zou D; Kokubo Y; Takechi A; Kudoh S
    Int J Oncol; 2003 Feb; 22(2):281-8. PubMed ID: 12527923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291.
    Naglich JG; Jure-Kunkel M; Gupta E; Fargnoli J; Henderson AJ; Lewin AC; Talbott R; Baxter A; Bird J; Savopoulos R; Wills R; Kramer RA; Trail PA
    Cancer Res; 2001 Dec; 61(23):8480-5. PubMed ID: 11731431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity.
    London CA; Sekhon HS; Arora V; Stein DA; Iversen PL; Devi GR
    Cancer Gene Ther; 2003 Nov; 10(11):823-32. PubMed ID: 14605668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protease inhibitor treatments reveal specific involvement of matrix metalloproteinase-9 in human adipocyte differentiation.
    Bourlier V; Zakaroff-Girard A; De Barros S; Pizzacalla C; de Saint Front VD; Lafontan M; Bouloumié A; Galitzky J
    J Pharmacol Exp Ther; 2005 Mar; 312(3):1272-9. PubMed ID: 15537822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy, IL-12 gene therapy and combined adjuvant therapy of HPV 16-associated MHC class I-proficient and -deficient tumours.
    Indrová M; Bieblová J; Jandlová T; Vonka V; Pajtasz-Piasecka E; Reinis M
    Int J Oncol; 2006 Jan; 28(1):253-9. PubMed ID: 16328003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
    Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
    Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.